assessment for early detection of heart
attacks, the #1 global cause of mortality
Heart attacks are the number one cause of death globally, responsible for more than 9 million deaths annually. The accumulative lifetime cost of treating a patient post-heart attack in the United States can reach $1 million, placing an enormous economic burden on financial and healthcare systems. This total market is estimated to reach $1 trillion by 2035.
Early and accurate detection of coronary artery disease (CAD) is a significant clinical challenge. Currently, physicians have limited front-line diagnostic tools for the early detection of CAD. Existing methods are either inaccurate (ECG), highly invasive (Angiogram), or very costly (CT).
AccuLine is developing CORA – a short exam that indicates a patients’ coronary artery disease risk level. This technology functions by detecting two new biomarkers discovered by AccuLine, and is based on patented enhanced waveform display and AI-powered algorithms analyzing the electric activity of the heart. The exam is easy to perform in any setting by any medical staff personnel, and the results are provided immediately. CORA has the potential to save the lives of millions of patients worldwide, while simultaneously decreasing healthcare-related costs.